Uric Acid News and Research

RSS

Study throws light on why gout not well managed in many patients

A study published online this month in the Arthritis Care and Research journal is shedding light on why gout, a painful and common form of arthritis, is not well managed in many patients. The journal is published by the American College of Rheumatology.

22 Jan 2016

Study advances understanding of chronic and progressive nature of gout if treated inadequately

Emeritus professor of medicine, Elisio Pascual, at the Miguel Hernández Univeristy in Elche and former head of the Rheumatology Unit at Alicante University Hospital has published a research paper presenting previously unknown data that contribute to our understanding of gout as a crystal deposition disease.

29 Dec 2015

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.

24 Dec 2015

Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

The U.S. Food and Drug Administration today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approved to reduce the production of uric acid in the body.

22 Dec 2015

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

The presence of tophi - crystal deposits of uric acid found on the surface of the joints or in the skin and cartilage - in people with gout can increase their risk of developing cardiovascular disease, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco.

9 Nov 2015

PolyU researchers develop novel biosensor for measuring glucose level in saliva

Diabetic patients have to monitor blood glucose regularly and frequently, but conventional method of taking blood sample for measuring glucose level is painful. It is therefore important to develop high performance biological sensors for monitoring the glucose level at a reasonable cost.

3 Nov 2015

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

16 Oct 2015

Mysterious kidney disease may be caused by chronic dehydration tied to global climate change

A mysterious kidney disease that has killed over 20,000 people in Central America, most of them sugar cane workers, may be caused by chronic, severe dehydration linked to global climate change, according to a new study by Richard J. Johnson, MD, of the University of Colorado Anschutz Medical Campus.

9 Oct 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

UT Southwestern Medical Center has joined an international clinical trial studying whether a drug traditionally used to treat gout can help prevent kidney damage in patients with Type 1 diabetes.

15 Sep 2015

University of Otago research backs the belief that eating tomatoes can cause gout to flare up

People who maintain that eating tomatoes can cause their gout to flare up are likely to welcome new research from New Zealand's University of Otago that has, for the first time, found a biological basis for this belief.

20 Aug 2015

Study reveals new gene that plays crucial role in ASD

A study carried out by the Laboratoire Neurobiologie des Interactions Cellulaires et Neurophysiopathologie (CNRS/Aix-Marseille Université), in collaboration with clinicians from Marseilles Public Hospitals (AP-HM) and scientists from the Salk Institute in San Diego (US), has revealed a new gene that plays a crucial role during early development in humans and whose under-expression may induce certain autistic traits.

4 Aug 2015

Common gout medications may offer protection from alcohol-induced liver disease, inflammation

New research in mice shows that two commonly used gout medications, which target uric acid and adenosine triphosphate, may offer protection from alcohol-induced liver disease and inflammation.

3 Aug 2015

Sugar-sweetened beverages increase risk factors for cardiovascular disease

Beverages sweetened with low, medium and high amounts of high-fructose corn syrup significantly increase risk factors for cardiovascular disease, even when consumed for just two weeks by young, healthy men and women, reports a team of researchers at the University of California, Davis.

23 Apr 2015

Children who eat certain types of food more likely to contract Epstein-Barr virus

A new study by UNC Charlotte scholars is shedding light on the connection between diet and a common childhood disease.

9 Apr 2015

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta Pharmaceuticals LLC, today announced that the Journal of Clinical Rheumatology published a comprehensive review of a post-hoc safety analysis that was completed for Krystexxa (pegloticase), including data from the two pivotal randomized Phase III trials and one open-label extension trial.

14 Dec 2014

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received US FDA and Taiwan FDA approval of a protocol for a Phase II clinical trial of its AC-201 controlled-release (CR) tablets for the indications of high blood uric acid level and gout.

14 Dec 2014

Gout attacks are most common at night

Research, published today, has shown that an acute gout attack is more than twice as likely to occur during the night or early morning hours as during the day. The increased prevalence of gout attacks at night time was observed even after 24 hours with no alcohol and low purine intake.

11 Dec 2014

Montmorency cherry concentrate helps reduce effects of gout

Drinking Montmorency concentrate significantly helps to reduce the effects of the painful condition gout, according to new research.

3 Oct 2014